Genomic Health, Inc.

Genomic Health, Inc. is a pioneering company in the field of genomic testing and personalised medicine. Established with the vision of transforming cancer care, the company focuses on providing innovative diagnostic solutions that empower patients and healthcare providers.

With a commitment to improving patient outcomes, Genomic Health develops tests that help in the early detection and treatment of various cancers. Their flagship products include the Oncotype DX test, which assesses the likelihood of cancer recurrence and the potential benefit of chemotherapy for breast cancer patients.

The company operates at the intersection of technology and healthcare, leveraging advanced genomic science to deliver actionable insights. By analysing genetic information, Genomic Health enables tailored treatment plans that are specific to individual patient profiles.

In addition to its core offerings, Genomic Health is dedicated to research and development, continuously seeking to expand its portfolio of diagnostic tests. The company collaborates with leading academic institutions and healthcare providers to advance the understanding of cancer genomics.

Genomic Health’s mission is to provide patients with the information they need to make informed decisions about their treatment options. They strive to enhance the quality of life for cancer patients through precision medicine.

Headquartered in the UK, Genomic Health is well-positioned to serve a global market, with a focus on expanding access to its innovative tests across Europe and beyond.

As a leader in the genomic testing industry, Genomic Health is committed to ethical practices and ensuring the highest standards of quality in its products. The company believes in the power of genomics to change lives and is dedicated to making a positive impact on cancer care worldwide.